Table 1.

Available meningococcal vaccines.^35,105-110

Type	Formulation	Serogroups	Trade name	Manufacturer	Carrier protein	Age group approved
Polysaccharide	MPSV-4	A-C-W-Y	Menomune	Sanofi Pasteur	—	≥ 2 y – 65 y
	MPSV-4	A-C-W-Y	Mencevax	GSK*	—	≥ 2 y
		A-C-W	MencevaxACW	GSK*	—	≥ 2 y
		A-C-W	MenVax ACW	Bio-Manguinhos	—	≥ 2 y
		A-C	Men AC	Sanofi-Pasteur	—	≥ 2 y
Conjugate	MenACWY-DT	A-C-W-Y	Menactra	Sanofi-Pasteur	DT	9 mo – 55 y
	MenACWY-CRM	A-C-W-Y	Menveo	Novartis	CRM197	2 mo – 55 y
	MenACWY-TT	A-C-W- Y	Nimenrix	GSK*	TT	≥ 6 w
	Hib-MenCY-TT	C-Y	MenHibrix	GSK*	TT	6 w -18 mo
	MCC-TT/Hib-TT	C	Menitorix	GSK*	TT	≥ 6 w – 2 y
	MCC-CRM	C	Menjugate	GSK*	CRM197	≥ 6 w – 65 y
	MCC-CRM	C	Meningitec	Pfizer	CRM197	≥ 6 w – 65 y
	MCC-TT	C	NeisVac-C	Baxter Healthcare	TT	≥ 8 w – 65 y
	PsA-TT	A	MenAfriVac	SIIL#	TT	3 m – 29 y
Protein	MenB-4C	B	Bexsero	Novartis	—	2m-25 y
	MenB-FHbp	B	Trumenba	Wyeth	—	10–25 y

GSK, GlaxoSmithKline; SIIL, Serum Institute of India Ltd, India.